نتایج جستجو برای: glycemic benefit of sglt2 inhibitors

تعداد نتایج: 21186431  

2016
Lei Yu Qiaozhi Xu Ping Hou Hong Zhang

BACKGROUND Familial renal glucosuria (FRG) is characterized by persistent glucosuria in the presence of normal serum glucose concentrations, and the absence of other impairments of tubular function. Mutations in the sodium-glucose co-transporter 2 (SGLT2) gene (SLC5A2) are causative of FRG the long-term outcome of which is well know. In the search for potential new drug targets for SGLT2 inhibi...

2017
Monish S Raut Arun Maheshwari

We are thankful for the comments on ‘Sodium glucose co-transporter (SGLT2) inhibitor: Patient safety and clinical importance’, and we appreciate the concern raised for its risk of euglycemic diabetic ketoacidosis (DKA). During clinical development programs for a new drug approval, it is not uncommon that some unexpected safety issues may go unobserved. Interestingly, the incidence of ketoacidos...

Journal: :Biomedicines 2023

Sodium-glucose cotransporter 2 (SGLT2) serves as a critical glucose transporter that has been reported to be overexpressed in cancer models, followed by increased uptake both mice and humans. Inhibition of its expression can robustly thwart tumor development vitro vivo. SGLT2 inhibitors are comparatively new class antidiabetic drugs have demonstrated anticancer effects several malignancies, inc...

Journal: :Molecules 2016
Chang-Ik Choi

Diabetes mellitus is a chronic condition associated with the metabolic impairment of insulin actions, leading to the development of life-threatening complications. Although many kinds of oral antihyperglycemic agents with different therapeutic mechanisms have been marketed, their undesirable adverse effects, such as hypoglycemia, weight gain, and hepato-renal toxicity, have increased demand for...

2013
Udaya M. Kabadi

SGLT2 inhibitors improve hyperglycemia with a decline in body weight and blood pressure, the outcomes touted to be of major importance in management of type 2 diabetes. However, the efficacy in lowering glycemia is very modest and imparts an undue cost burden on patients. Moreover, the declines in body weight and blood pressure are slight at best and orthostatic hypotension and its manifestatio...

Journal: :Hellenic Journal of Cardiology 2021

Journal: :The Journal of Clinical Endocrinology & Metabolism 2015

Journal: :American Journal of Physiology-Renal Physiology 2018

Journal: :Circulation 2021

HomeCirculationVol. 143, No. 18Are SGLT2 Inhibitors New Hypertension Drugs? Free AccessEditorialPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyRedditDiggEmail Jump toFree AccessEditorialPDF/EPUBAre Kazuomi Kario, MD, PhD Keith C. Ferdinand, MD Wanpen VongpatanasinMD KarioKazuomi Kario PhD, Div...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید